Lexeo Therapeutics, Inc. (LXEO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 28, 2024, discloses the results of the 2024 Annual Meeting of Stockholders held virtually on June 25, 2024. Lexeo Therapeutics, Inc., a Delaware corporation, reported on the election of directors and the ratification of its independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes rather than financial performance.
Material Changes and Voting Results
The following proposals were voted upon by stockholders:
- Proposal 1: Election of Class I Director
- Mette Kirstine Agger was elected to serve until the 2027 Annual Meeting.
- Voting Results: 14,499,254 votes FOR; 7,450,057 votes WITHHELD; 1,249,160 Broker Non-Votes.
- Proposal 2: Ratification of Independent Auditor
- Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Voting Results: 23,194,982 votes FOR; 3,088 votes AGAINST; 401 votes ABSTAIN.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. For further details on the proposals, the filing references the Proxy Statement filed on April 26, 2024.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to calculate the percentage of votes cast for each proposal.
- Review the April 26, 2024 Proxy Statement for detailed biographies of the elected director and the rationale for the auditor selection.
- Confirm the company's emerging growth company status, as indicated by the checkmark in the filing header.